BioHarvest Sciences (NASDAQ:BHST – Get Free Report) is one of 55 public companies in the “Personal Care Products” industry, but how does it compare to its peers? We will compare BioHarvest Sciences to related businesses based on the strength of its risk, valuation, dividends, analyst recommendations, institutional ownership, profitability and earnings.
Insider & Institutional Ownership
49.3% of shares of all “Personal Care Products” companies are owned by institutional investors. 11.9% of shares of all “Personal Care Products” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares BioHarvest Sciences and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioHarvest Sciences | -34.67% | -55.88% | -26.59% |
| BioHarvest Sciences Competitors | -3.83% | -62.00% | 0.35% |
Volatility and Risk
BioHarvest Sciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, BioHarvest Sciences’ peers have a beta of 0.80, indicating that their average stock price is 20% less volatile than the S&P 500.
Earnings & Valuation
This table compares BioHarvest Sciences and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BioHarvest Sciences | $34.51 million | -$11.14 million | -2.30 |
| BioHarvest Sciences Competitors | $7.92 billion | $1.10 billion | 10.32 |
BioHarvest Sciences’ peers have higher revenue and earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a breakdown of recent recommendations for BioHarvest Sciences and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioHarvest Sciences | 1 | 0 | 2 | 0 | 2.33 |
| BioHarvest Sciences Competitors | 906 | 2950 | 3665 | 229 | 2.42 |
BioHarvest Sciences currently has a consensus target price of $6.50, indicating a potential upside of 432.79%. As a group, “Personal Care Products” companies have a potential upside of 1.86%. Given BioHarvest Sciences’ higher probable upside, equities analysts plainly believe BioHarvest Sciences is more favorable than its peers.
Summary
BioHarvest Sciences peers beat BioHarvest Sciences on 9 of the 13 factors compared.
About BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company that develops plant-based ingredients and consumer products using its proprietary Botanical Synthesis platform. The technology grows selected plant cells in controlled bioreactors, offering an alternative to cultivating and processing whole plants. The company’s best-known product is VINIA, a dietary supplement made from red grape cells. BioHarvest also works to develop additional botanical ingredients and products for consumer markets, including nutraceuticals and cosmetics.
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
